Scientific Leap in Veterinary Medicine: New Drug May Extend Dogs' Lifespan by Years

The biotechnology company Loyal has announced a significant advancement in the development of its experimental drug “LOY-002,” specifically designed to extend the lifespan of dogs and combat signs of aging.

This development is a potential game-changer in the field of veterinary medicine, as the drug approaches final approval stages.

The new drug focuses on reducing the effects of the hormone “Insulin-like Growth Factor 1” (IGF-1), which is linked to rapid aging in dogs, particularly in large breeds.

According to studies, reducing this hormone may help slow physical decline and maintain activity and mobility for longer periods in older dogs.

The drug comes in the form of chewable tablets with a meat flavor, making it easy to administer to pets without the need for complicated treatment procedures.

It is aimed at dogs over the age of 10, with the goal of improving their quality of life, not just treating age-related diseases.

The company reported that the drug has passed an important regulatory phase with the U.S. Food and Drug Administration, bringing it closer to final approval for commercial use.

Extensive clinical trials are currently underway to confirm its efficacy and safety before it hits the market.

If positive results continue, the drug is expected to be available in veterinary clinics by the end of 2027, making it the first treatment of its kind aimed at extending the lifespan of pets.

Researchers believe this development may open the door to broader research in extending human lifespan, given the similarities in some biological pathways between dogs and humans.